Literature DB >> 22783408

Tanshinone IIA arrests cell cycle and induces apoptosis in 786-O human renal cell carcinoma cells.

Xianli Wei1, Lunbin Zhou, Liangyong Hu, Yaoxiong Huang.   

Abstract

Tanshinone IIA (Tan IIA), isolated from the Chinese medicinal herb Danshen, has been reported to have anticancer effects in several tumor models, while its effects on renal cell carcinoma have not been studied. In the present study, we evaluated the effects of Tan IIA on growth inhibition and apoptosis in the renal cancer cell line 786-O and its mechanism of action. Results of the MTT assay indicated that the treatment of 786-O cells with Tan IIA resulted in a concentration-dependent decrease in cell viability. Flow cytometry analysis revealed that Tan IIA treatment caused apoptosis following cell cycle perturbation. Furthermore, we examined the expression of cell cycle and apoptosis-related proteins using immunoblotting, which indicated an upregulation of p53, p21, bax and caspase-3 in Tan IIA-treated cells compared with Tan IIA-untreated cells. These results suggest that the activation of p53 and the upregulation of its target genes, including p21 and bax, may be involved in the mitochondrial apoptosis induced by Tan IIA in 786-O cells.

Entities:  

Year:  2012        PMID: 22783408      PMCID: PMC3389690          DOI: 10.3892/ol.2012.626

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  17 in total

1.  Tanshinone IIA inhibits LPS-induced NF-kappaB activation in RAW 264.7 cells: possible involvement of the NIK-IKK, ERK1/2, p38 and JNK pathways.

Authors:  Seon Il Jang; Hyung Jin Kim; Young-Jun Kim; Seung-Il Jeong; Yong-Ouk You
Journal:  Eur J Pharmacol       Date:  2006-05-06       Impact factor: 4.432

2.  Protective effect of tanshinone IIA on human umbilical vein endothelial cell injured by hydrogen peroxide and its mechanism.

Authors:  Rong Lin; Wei-Rong Wang; Jun-Tian Liu; Guang-De Yang; Chun-Jie Han
Journal:  J Ethnopharmacol       Date:  2006-05-16       Impact factor: 4.360

3.  Experimental study of the anti-cancer mechanism of tanshinone IIA against human breast cancer.

Authors:  Qing Lu; Purong Zhang; Xin Zhang; Jie Chen
Journal:  Int J Mol Med       Date:  2009-12       Impact factor: 4.101

4.  WAF1 retards S-phase progression primarily by inhibition of cyclin-dependent kinases.

Authors:  V V Ogryzko; P Wong; B H Howard
Journal:  Mol Cell Biol       Date:  1997-08       Impact factor: 4.272

5.  Potential anticancer activity of tanshinone IIA against human breast cancer.

Authors:  Xiujie Wang; Yuquan Wei; Shulan Yuan; Guanjian Liu; Yanrong Lu; Jie Zhang; Wendong Wang
Journal:  Int J Cancer       Date:  2005-09-20       Impact factor: 7.396

6.  Cytotoxic synergy between the multikinase inhibitor sorafenib and the proteasome inhibitor bortezomib in vitro: induction of apoptosis through Akt and c-Jun NH2-terminal kinase pathways.

Authors:  Chunrong Yu; Bret B Friday; Jin-Ping Lai; Lin Yang; Jann Sarkaria; Neil E Kay; Christopher A Carter; Lewis R Roberts; Scott H Kaufmann; Alex A Adjei
Journal:  Mol Cancer Ther       Date:  2006-09       Impact factor: 6.261

7.  Growth inhibition and induction of apoptosis and differentiation of tanshinone IIA in human glioma cells.

Authors:  Jing Wang; Xiujie Wang; Shu Jiang; Shulan Yuan; Ping Lin; Jie Zhang; Yanrong Lu; Qi Wang; Zhujuan Xiong; Yaying Wu; Jingjing Ren; Hongliang Yang
Journal:  J Neurooncol       Date:  2006-09-06       Impact factor: 4.130

Review 8.  Regulation of p53 downstream genes.

Authors:  W S el-Deiry
Journal:  Semin Cancer Biol       Date:  1998       Impact factor: 15.707

9.  Tanshinone (Salviae miltiorrhizae extract) preparations attenuate aminoglycoside-induced free radical formation in vitro and ototoxicity in vivo.

Authors:  Ai-Mei Wang; Su-Hua Sha; Wojciech Lesniak; Jochen Schacht
Journal:  Antimicrob Agents Chemother       Date:  2003-06       Impact factor: 5.191

10.  p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs.

Authors:  M Müller; S Wilder; D Bannasch; D Israeli; K Lehlbach; M Li-Weber; S L Friedman; P R Galle; W Stremmel; M Oren; P H Krammer
Journal:  J Exp Med       Date:  1998-12-07       Impact factor: 14.307

View more
  11 in total

1.  Tanshinone IIA Inhibits Osteosarcoma Growth through a Src Kinase-Dependent Mechanism.

Authors:  Chao Hu; Xiaobin Zhu; Taogen Zhang; Zhouming Deng; Yuanlong Xie; Feifei Yan; Lin Cai
Journal:  Evid Based Complement Alternat Med       Date:  2021-06-30       Impact factor: 2.629

2.  Tanshinone IIA pretreatment promotes cell survival in human lung epithelial cells under hypoxia via AP-1-Nrf2 transcription factor.

Authors:  Seema Yadav; Mrinalini Singh; Som Nath Singh; Bhuvnesh Kumar
Journal:  Cell Stress Chaperones       Date:  2020-03-06       Impact factor: 3.667

3.  The antitumor effect of tanshinone IIA on anti-proliferation and decreasing VEGF/VEGFR2 expression on the human non-small cell lung cancer A549 cell line.

Authors:  Jun Xie; Jiahui Liu; Heng Liu; Shihui Liang; Meigui Lin; Yueyu Gu; Taoli Liu; Dongmei Wang; Hui Ge; Sui-Lin Mo
Journal:  Acta Pharm Sin B       Date:  2015-09-26       Impact factor: 11.413

4.  Tanshinone IIA combined with adriamycin inhibited malignant biological behaviors of NSCLC A549 cell line in a synergistic way.

Authors:  Jun Xie; Jia-Hui Liu; Heng Liu; Xiao-Zhong Liao; Yuling Chen; Mei-Gui Lin; Yue-Yu Gu; Tao-Li Liu; Dong-Mei Wang; Hui Ge; Sui-Lin Mo
Journal:  BMC Cancer       Date:  2016-11-18       Impact factor: 4.430

5.  Protective effect of tanshinone IIA against cardiac hypertrophy in spontaneously hypertensive rats through inhibiting the Cys-C/Wnt signaling pathway.

Authors:  Jun Feng; Hua-Wen Chen; Li-Juan Pi; Jin Wang; Da-Qian Zhan
Journal:  Oncotarget       Date:  2017-02-07

Review 6.  Targeting VEGF/VEGFRs Pathway in the Antiangiogenic Treatment of Human Cancers by Traditional Chinese Medicine.

Authors:  Cheng Zhang; Ning Wang; Hor-Yue Tan; Wei Guo; Sha Li; Yibin Feng
Journal:  Integr Cancer Ther       Date:  2018-05-28       Impact factor: 3.279

7.  Tanshinone IIA combined with cisplatin synergistically inhibits non-small-cell lung cancer in vitro and in vivo via down-regulating the phosphatidylinositol 3-kinase/Akt signalling pathway.

Authors:  Xiao-Zhong Liao; Ying Gao; Sheng Huang; Zhuang-Zhong Chen; Ling-Ling Sun; Jia-Hui Liu; Han-Rui Chen; Ling Yu; Jia-Xing Zhang; Li-Zhu Lin
Journal:  Phytother Res       Date:  2019-07-03       Impact factor: 5.878

Review 8.  Tanshinones: sources, pharmacokinetics and anti-cancer activities.

Authors:  Yong Zhang; Peixin Jiang; Min Ye; Sung-Hoon Kim; Cheng Jiang; Junxuan Lü
Journal:  Int J Mol Sci       Date:  2012-10-22       Impact factor: 5.923

9.  High expression of FER tyrosine kinase predicts poor prognosis in clear cell renal cell carcinoma.

Authors:  Can Wei; Song Wu; Xianxin Li; Yadong Wang; Rui Ren; Yongqing Lai; Jiongxian Ye
Journal:  Oncol Lett       Date:  2012-11-16       Impact factor: 2.967

Review 10.  Roles of Reactive Oxygen Species in Anticancer Therapy with Salvia miltiorrhiza Bunge.

Authors:  Yu-Chiang Hung; Tai-Long Pan; Wen-Long Hu
Journal:  Oxid Med Cell Longev       Date:  2016-08-04       Impact factor: 6.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.